However, Rig-I−/− CD8+ T cells were more sensitive to inhibitors of PI3K, AKT, and glycolysis, indicating that Rig-I negatively regulates the anti-tumour activity of CD8+ T cells through the PI3K/AKT/glycolysis signalling pathway. Here, RIGI is linked to neoplasm.